Positive 5-year data argue for early identification and treatment of symptomatic patients in whom transcatheter edge-to-edge repair is appropriate for heart failure with secondary mitral regurgitation.
Encouraging findings from this sham-controlled study of the Carillon device for transvenous mitral annuloplasty in functional mitral regurgitation pique interest in the large ongoing CARILLON trial.
The COAPT trial finds transcatheter mitral valve repair to be safe and highly effective in a setting with no good treatment options: symptomatic mitral regurgitation secondary to heart failure.
The mitral valve poses anatomic challenges to transcatheter treatment that the aortic valve doesn’t. Here’s a glimpse into six ongoing studies designed to overcome them.